Fighting the Dangerous Increase of Multidrug-Resistant Microbes

Genetic Engineering & Biotechnology NewsRead the rest

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

Cision PR NewswireRead the rest

Forge Therapeutics To Present At The 18th Annual Needham & Company Healthcare Conference

Cision PR NewswireRead the rest

Anti-infective Drugs Market is expected to reach over $125 billion in 2020

Insider TradingsRead the rest

Why San Diego leaders must forge international economic partnerships

San Diego Union TribuneRead the rest

Forge Therapeutics And Collaborators From Evotec And USC Present New Efficacy Data At 2017 Keystone Symposia Conference

Cision PR NewswireRead the rest

Forge Therapeutics Announces Participation In Upcoming Scientific And Industry Events

Cision PR NewswireRead the rest

Forge & Evotec Expand Strategic Alliance With Launch Of BLACKSMITH Platform To Discover Novel Metalloenzyme Inhibitors Across Broad Therapeutic Areas

Cision PR NewswireRead the rest

Forge Therapeutics To Participate In Antimicrobial Resistance Panel At 2017 BIO Investor Forum

Markets InsiderRead the rest

Forge Therapeutics To Participate In Antimicrobial Resistance Panel At 2017 BIO Investor Forum

Cision PR NewswireRead the rest

Forge Therapeutics And Evotec Present Efficacy Data For LpxC Inhibitor In Urinary Tract, Lung, Thigh, And Abdominal Infection Models At ASM ESCMID 2017

Cision PR NewswireRead the rest

Forge Therapeutics Forms Scientific Advisory Board with World Renowned Antibiotic and Drug Development Experts

Pharmacy ChoiceRead the rest

Forge Therapeutics Forms Scientific Advisory Board with World Renowned Antibiotic and Drug Development Experts

Cision PR NewswireRead the rest

San Diego start-ups navigate mixed venture capital landscape in 2nd quarter

San Diego Union TribuneRead the rest

Forge Therapeutics And Evotec Present First Efficacy Data For LpxC Inhibitor In UTI Model At ASM Microbe 2017

Cision PR NewswireRead the rest

Forge Therapeutics And Evotec Present First Efficacy Data For LpxC Inhibitor In UTI Model At ASM Microbe 2017

Crossroads TodayRead the rest

Forge Therapeutics Attracts Biotechnology Leaders To Join Expanded Board Of Directors

Crossroads TodayRead the rest

Forge Therapeutics Attracts Biotechnology Leaders To Join Expanded Board Of Directors

PR newswireRead the rest

Forge Therapeutics Raises $15M to Take on Drug-Resistant Superbugs

XconomyRead the rest

Forge Therapeutics Raises $15M Series A Financing to Develop First Novel Gram-Negative Antibiotic in Decades

Crossroads TodayRead the rest

Forge Therapeutics Raises $15M Series A Financing to Develop First Novel Gram-Negative Antibiotic in Decades

PR NewswireRead the rest

Evotec’s Partner Forge Therapeutics Receives Prestigious CARB-X Research Award

BusinessWireRead the rest

Forge Therapeutics Wins Powered by CARB-X Research Award of $8.8M to Accelerate Development of its LpxC Antibiotic to Kill the World’s Deadliest ‘Superbugs’

PR NewswireRead the rest

Forge Therapeutics to Present at the 9th Annual Biotech Showcase

click hereRead the rest

Forge Therapeutics Announces Novel Antibiotic Presentation at the American Society of Microbiology Conference on Antibacterial Development

click hereRead the rest

Forge, ties up with Evotec to advance novel Gram-negative antibiotic programme targeting ‘LpxC’ to treat bacterial infections

click hereRead the rest

Evotec and Forge Therapeutics Form Strategic ‘Superbug’ Alliance

click hereRead the rest